eMed's $200M Series A Ties AI Population Health to Capitated GLP-1 Programs
eMed raised $200M at a $2B+ valuation to deploy AI-driven metabolic care pathways with outcomes-based pricing. Employers gain 20-30% cost savings, forcing rivals to adopt risk-sharing models.

